

November 07, 2023

То

The Secretary, Listing Department BSE Limited (SME), Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001

Scrip No. 543363 BSE Symbol: PREVEST

Sub: Submission of Investor Presentation to be made to Analysts/Investors

Please find enclosed herewith the investor presentation to be made to Analysts/Investors on the Financial Results of Prevest Denpro Limited for the quarter and half year ended September 30, 2023.

This presentation is being submitted in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The same is also made available on the Company's website www.prevestdenpro.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For Prevest Denpro Limited AMAN Digitally signed by AMAN SADHOTRA SADHOTRA Date: 2023.11.07 17:01:51 +05'30'

Aman Sadhotra Company Secretary and Compliance Office M. No- 66562

Prevest Denpro Limited, CIN: L85199JK1999PLC001969, Registered Office & Factory: Unit II, Export Promotion Industrial Park (EPIP), Bari Brahmana, Jammu (J&K)-181133,India. Phone: + 0191 350 6858, 8899074151, E-mail: info@prevestdenpro.com, Web: www.prevestdenpro.com



EARNING PRESENTATION

HY1 FY 2023-24



Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Prevest Denpro Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost overruns on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



	REVENUE (Rs.Lakhs)	PAT (Rs.Lakhs)	EBITDA (Rs.Lakhs)
HY1 FY 2023-24	2791.41	782.49	1081.49
HY1 FY 2022-23	2501.22	701.40	1022.77

PAT MARGIN

EBITDA MARGIN

28.03%

38.74%

28.04%

40.89%



Strategic Levers Of Growth



0

C

Presence in new geographic location

Improved client satisfaction Leading to new client acquisitions


وَرَ



Growing dental industry

...

Business Highlight







ACA

Export to over +90 countries worldwide

+60 Dealers in India

+90 Overseas Agents

Board Of Directors



(Chairman and MD)

Namrata Modi

Whole Time Director and CFO

Vaibhav Munjal

Additional Executive Director

Dr. Sai Kalyan Surapaneni

R&D Director

Niharika Modi Non-Executive Director

Dr. Nikhil Shrikant Bobade

Independent Director

Dr. Sudeep Haralakatte Murthy

Independent Director

CA Pardeep Gandotra

Additional Independent Director

Advisiory Board

Dr. Carolyn Primus

(BS, MS, PhD), USA A renowned scientist, inventor, educationist and author

Prof. Francesco Inchingolo

(MD,DMD, O.M.FS, M.P.H), Italy Professor in Dentistry, University of Bari "Aldo Moro", Italy

Prof. Dr. Alka Beotra

(MSc PhD) Director Qatar Analytics and **BioResearch Laboratory**

Dr. Vishal V. Pande (M. Pharma, PhD) Principal, N. N. Sattha College of Pharmacy, Ahmednagar

Dr. Shishir Singh (MDS, PhD) Professor, Terna Dental College, Navi Mumbai

Dr. KV Ramana Reddy

(MDS, FDSRCS (England), FDSRCSI (Ireland)

Principal, Army College of Dental Science, Hyderabad

Comprehensive Product Portfolio

Product Categories	No. of products	
Endodontics Materials	+25	Roo
Cements & Liners	+16	Luti
Composites	+8	Den
Orthodontics Materials	+2	Use
Finishing & Polishing	+5	Poli
Auxiliaries	+6	Sup
Impression Materials	+6	Rec
Tooth Whitening	+4	Whi
Haemostatic Materials	+2	Con
Temporary Materials	+5	Tem
Lab Materials	+8	Use pros
Adhesives, Bonding Agents & Etchants	+8	Bon dent
Dental 3D Printing Resins	+7	Fab Tem Brid

Product Usage

ot canal treatment

ing and restorative applications

ntal restoration and filling

ed for Orthodontic applications

ishing & oral Prophylaxis

oport in various dental procedures

cording dental impressions

itening of discoloured teeth

ntrols haemostasis during dental procedures

nporary restoration and fillings

ed in the dental laboratory in the fabrication of artificial osthesis

nding agents and etching materials used as adhesive in ntistry

prication of Surgical Guides; dentine bases; nporary and Permanent (Ceramic) Crowns; dges; Cast Models





Our New Products Segment





3D DENTAL RESINS

DISINFECTANT PRODUCT

Quality Accreditations

With a focus on product quality, the company has successfully implemented a very effective quality management system which has been approved by TUV SUD, Germany. With the strong quality management system, all production processes are subjected to stringent monitoring and intensive testing thus ensuring consistent quality and safety of our products. As a result of implementation of strong quality management system, Prevest DenPro has been certified with ISO 13485-2016, USFDA and EC Certificate. The company has also pass through the Saudi FDA regulatory compliances and has been successfully granted SFDA. The company has also received MDSAP certification which is a conformity to Medical Device Single Audit Program for USA, Canada & Brazil







Strategic Technical Research and Tie-up

The Company has entered into collaboration with the following reputed dental universities & institutions for exchange of technical knowledge and conducting training & research on dental materials. The Company has also entered into technology transfer agreement with Sree Chitra Tirunal Institute for Medical Sciences & Technology, Kerala for know-how for the manufacture of bioactive bone grafting materials.



and Opportunities **Strengths**



Well - established global sales network

With consistent marketing efforts over the years, the Company has been able to make its product reach to over 90 countries with network of 53 national dealers and 91 overseas agents



B2B and B2C Sales Model

Along with B2B Sales (i.e. sales to dealers and agents), the Company is connecting directly with consumers through its own online portal (prevestdirect.com), GEM Portal and other online marketplaces




Comprehensive Product Portfolio

In the last two decades of operations, the Company has been successful in establishing a comprehensive portfolio of over 100 dental products covering endodontics, orthodontics, composites, impression materials, finishing & polishing materials, auxiliaries' materials. hemostatic materials. temporary materials, lab materials, adhesives, cement & liners and tooth whitening.



Research Collaboration with prominent academic institutes

The Company has entered into collaboration with 12 reputed dental universities & institutions of India for exchange of technical knowledge and conducting training & research on dental materials.



Strong Advisory Board & Management

The promoters of the company have a combined experience of over 40 years in dental industry backed up with strong management team. It also has an advisory board of experienced & highly educated dental professionals.

Finance



Balance Sheet (Standalone)

Particulars

<u>l.</u> 1	<u>EQUITY & LIABILITIES</u> Shareholders Funds Share Capital Reserves & Surplus
2	Share Application Money Pending Allotments
3	Non- current Liabilities Long- Term Borrowings Deferred Tax Liabilities (Net)
4	Current Liabilities Trade Payables 1. total outstanding dues of micro enterprises and small enterprises
	 2. total outstanding dues of trade payables other than micro and small enterprises Other Current Liabilities Short- Term Provisions Total Equity & Liabilities
1	Non- Current Assets <u>Property, Plant & Equipment and Intangible Assets</u> Property, Plant & Equipment Capital Works in progress
2	Non-Current Investments Current Assets Current Investment Inventories Trade receivables Cash & cash equivalents Short- Term Loans & Advances Other Current Assets

Total Assets

As at September 30, 2023	As at March 31, 2023
Un-Audited	Audited
1 200 20	-
1,200.30 6,830.25	1,200.30 6,079.44
- 8,030.55	- 7,279.74
47.45	37.12
47.45	37.12
50.07	44 52
59.87	41.52
103.80	98.27
333.17 19.35	404.25
516.19	- 544.04
8,594.19	7,860.90
1,520.61	- 740.59
1,122.09	1,688.72
2,642.70	2,429.31
5.00	
5.00	
142.90 650.30	119.40 478.89
776.98	478.89 430.47
3,946.45	3,900.31
134.36	174.16
295.50	328.37
5,946.49	5,431.59
8,594.19	7,860.90

Balance

Sheet (Consolidated)

Particulars

EQUITY & LIABILITIES Shareholders Funds Share Capital Reserves & Surplus

Share Application Money Pending Allotments

Non- current Liabilities Long- Term Borrowings Deferred Tax Liabilities (Net)

Current Liabilities Trade Payables

1. total outstanding dues of micro enterprises and small enterprises

total outstanding dues of trade payables other than micro and small enterprises
 Other Current Liabilities
 Short- Term Provisions

Total Equity & Liabilities

Non- Current Assets <u>Property, Plant & Equipment and Intangible Assets</u> Property, Plant & Equipment Capital Works in progress

Non-Current Investments

Current Assets Current Investment Inventories Trade receivables Cash & cash equivalents Short- Term Loans & Advances Other Current Assets

Total Assets

Rs In Lakh

As at September 30, 2023	As at March 31, 2023
Un-Audited	Audited
1,200.30	1,200.30
6,820.50	6,079.44
8,020.80	7,279.74
	-
47.45	37.12
47.45	37.12
59.87	41.52
103.87	98.27
336.86	404.25
19.35	
519.95	544.04
8,588.21	7,860.90
- 1,520.61	- 740.59
1,122.09	1,688.72
2,642.70	2,429.31
2,012.00	2,120101
142.90	119.40
650.54	478.89
776.72	430.47
3,950.15	3,900.31
129.21	174.16
295.99	328.37
5,945.51	5,431.59
8,588.21	7,860.90

Profit

and Loss (Standalone)

			Quarter Ended			Six Month Ended		Rs in Lakh Year Ended
	PARTICULARS	30-09-2023	30-06-2023	30-09-2022	30-09-2023	31-03-2023	30-09-2022	31-03-2023
	FAILTICOLARS	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Audited
1	Income From Operation	onduited	Ondudited	onadatted	onadalica	Addited	onadatted	Addited
	(a) Net Sales / Income from Operation (Net of Taxes)	1,317.78	1,339.40	1,144.72	2,657.17	2,604.08	2,381.33	4,985.41
	(b)Other Income	73.72	60.52	58.12	134.24	83.46	119.90	203.35
	Total Revenue	1,391.50	1,399.92	1,202.84	2,791.41	2,687.54	2,501.22	5,188.76
2	Expenses							
	(a) Cost of Material Consumed	351.01	352.84	306.26	703.84	599.78	676.29	1,276.08
	(b) Purchase of Stock-in- Trade							
		(5.09)	(9.21)	(4.69)	(14.30)	(6.25)	(9.04)	(15.29)
	(c)Changes in inventories of finished goods, work-in-progress and stock-in- trade	(3.03)	(3.21)	(4.05)	(14.30)	(0.23)	(3.04)	(13.23)
	(d) Finance Cost	-	-	-	-	-	-	-
	(d) Employee benefit expenses	230.71	239.60	196.11	470.32	435.41	383.66	819.07
	(e) Depreciation and amortization expenses	21.95	17.49	18.88	39.44	33.99	33.52	67.51
	(f) Other Expenses	290.49	259.57	201.83	550.06	518.18	427.53	945.71
	Total Expenses	889.07	860.30	718.39	1,749.37	1,581.12	1,511.97	3,093.09
					_,,,	_)=====	_,	0,000.00
3	Profit/(Loss) from before exceptional and extraordanry items (1-2)	502.43	539.62	484.45	1,042.05	1,106.42	989.25	2,095.68
	Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)	502.43	539.62	484.45	1,042.05	1,106.42	989.25	2,095.68
	Financial Cost							
		502.43	539.62	484.45	1,042.05	1,106.42	989.25	2,095.68
	Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)	502.45	559.02	404.43	1,042.05	1,100.42	969.25	2,093.00
4	Exceptional Item							
5	Profit/(Loss) from ordinary activities before tax (3+4)	502.43	539.62	484.45	1,042.05	1,106.42	989.25	2,095.68
6	Tax Expenses							
	Current Tax	113.84	135.39	140.23	249.23	230.29	285.87	516.16
	Earliyer Year Tax	-	-	-1.46	40.00	1.73	(1.46)	0.27
_	Deffered Tax	14.55	-4.22	12.47	10.33	4.78	3.45	8.24
/	Net Profit/(Loss) from Ordinary activity after tax (5-6)	374.04	408.45	333.21	782.49	869.61	701.40	1,571.01
8	Extraordinery Item (net of tax Rs expenses)	274.04	400 45	222.24	702.40	000.01	701 40	1 571 01
9	Net profit/(loss) for the period (7+8)	374.04	408.45	333.21	782.49	869.61	701.40	1,571.01
10	Details of Share Capital Daid up Equity Share Capital Eaco Value Rs 10/ each	120.00	120.00	120.00	120.00	120.00	120.00	120.00
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accunting year.							6,079.44
11	Earnings per Share (EPS) , in Rs (not annualised)							
	(Equity Share of face value of Rs 10/- each)							
	(a) Basic	3.12	3.40	2.78	6.52	7.25	5.84	13.09
	(b) Diluted	3.12	3.40	2.78	6.52	7.25	5.84	13.09



Profit

and Loss (Consolidated)

PARTICULARS

- Income From Operation

 (a) Net Sales / Income from Operation (Net of Taxes)
 (b)Other Income
 Total Revenue
- 2 Expenses(a) Cost of Material Consumed(b) Purchase of Stock-in- Trade

(c)Changes in inventories of finished goods, work-in-progress and stock-in- trade
(d) Finance Cost
(d) Employee benefit expenses
(e) Depreciation and amortization expenses
(f) Other Expenses

Total Expenses

3 Profit/(Loss) from before exceptional and extraordanry items (1-2)

Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4) Financial Cost

Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)

- 4 Exceptional Item
- 5 Profit/(Loss) from ordinary activities before tax (3+4)
- 6 Tax Expenses Current Tax Earliyer Year Tax Deffered Tax
- 7 Net Profit/(Loss) from Ordinary activity after tax (5-6)
- 8 Extraordinery Item (net of tax Rs expenses)
- 9 Net profit/(loss) for the period (7+8) Details of Share Capital
- 10 Paid up Equity Share Capital-Face Value Rs 10/- each

11

Reserve excluding, Revaluation Reserves as per balance sheet of previous accunting year.

11 Earnings per Share (EPS), in Rs (not annualised)

(Equity Share of face value of Rs 10/- each)

(a) Basic

(b) Diluted

Quarter Ended		Six Month Ended
30-09-2023	30-06-2023	30-09-2023
Unaudited	Unaudited	Unaudited
onduced	ondutied	Chaddhed
1,317.54	1,339.40	2,656.93
73.72	60.52	134.24
1,391.26	1,399.92	2,791.17
351.01	352.84	703.84
(5.33)	(9.21)	(14.54)
(3.33)	(3.21)	(14.34)
238.72	239.60	478.32
21.95	17.49	39.44
292.24	259.57	551.81
898.58	860.30	1,758.88
492.68	539.62	1,032.30
492.68	539.62	1,032.30
492.68	539.62	1,032.30
492.68	539.62	1,032.30
113.84	135.39	249.23
14.55	-4.22	10.33
364.29	408.45	772.74
364.29	408.45	772.74
	100.13	772.74
120.00	120.00	120.00
120.00	120.00	120.00

3.04	3.40	6.44
3.04	3.40	6.44

Cash Flow Statement

Particulars

Cash Flow From Operating Activities: Net Profit before tax as per Profit And Loss A/c Adjustments for: **Depreciation & Amortisation Expense** Interest Income Operating Profit Before Working Capital Changes Adjusted for (Increase)/ Decrease in: Short term provision Trade Receivables Inventories Other current assets Trade Payables Other Current Liabilities Cash Generated From Operations Appropriation of Profit Net Income Tax paid/ refunded Net Cash Flow from/(used in) Operating Activities: (A) Cash Flow From Investing Activities: Net (Purchases)/Sales of Fixed Assets (including capital work in progress) Interest Income Net Increase/(Decrease) in Current Investment Net Cash Flow from/(used in) Investing Activities: (B) Cash Flow from Financing Activities: Net Increase/(Decrease) in Long Term Borrowings Dividend paid Net Cash Flow from/(used in) Financing Activities (C) Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents As At Beginning of the Year Cash & Cash Equivalents As At End of the Year

	Rs. In Lakhs
For the Half- year ended Sept 30, 2023	Year Ended 31.03.2023
	Audited
- 1,042.05	- 2,095.68
39.44	67.51
(117.15)	(161.55)
964.34	2,001.64
	(9.88)
(346.52)	(198.37)
(171.41)	(152.52)
72.67	(95.64)
23.88	(23.94)
(71.08)	37.93
(492.46)	(442.43)
229.87	516.44
242.00	1,042.77
- -252.84	_ (1,352.77)
117.15	161.55
(28.50)	(46.50)
(164.19)	(1,237.72)
	_ (136.67)
(31.68)	
(31.68)	(136.67)
46.13	(331.62)
3,900.31	4,231.93
3,946.45	3,900.31
3,340.43	5,900.51

Cash Flow Statement (Consolidated)

Particulars

Cash Flow From Operating Activities: Net Profit before tax as per Profit And Loss A/c Adjustments for: Depreciation & Amortisation Expense Interest Income **Operating Profit Before Working Capital Changes** Adjusted for (Increase)/ Decrease in: Short term provision Trade Receivables Inventories Other current assets & Short-term loans & Advances Trade Payables **Other Current Liabilities** Cash Generated From Operations Appropriation of Profit Net Income Tax paid/ refunded Net Cash Flow from/(used in) Operating Activities: (A) Cash Flow From Investing Activities: Net (Purchases)/Sales of Fixed Assets (including capital work in progress) Interest Income Net Increase/(Decrease) in Current Investment Net Cash Flow from/(used in) Investing Activities: (B) Cash Flow from Financing Activities: Net Increase/(Decrease) in Long Term Borrowings **Dividend paid** Net Cash Flow from/(used in) Financing Activities (C) Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents As At Beginning of the Year Cash & Cash Equivalents As At End of the Year

For the Half- year ended	Year Ended
Sept 30, 2023	31.03.2023
Un-audited	Audited
- 1,032.30	2,095.68
39.44	67.51
(117.15)	(161.55)
954.59	2,001.64
	(9.88)
(346.26)	(198.37)
(171.65)	(152.52)
77.33	(95.64)
23.95	(23.94)
(67.39)	37.93
(484.01)	(442.43)
229.87	516.44
240.71	1,042.77
- -252.84	- (1,352.77)
117.15	161.55
(23.50)	(46.50)
(159.19)	(1,237.72)
-	_ (136.67)
(31.68)	
(31.68)	(136.67)
49.84	(331.62)
3,900.31	4,231.93
3,950.15	3,900.31

Rs. In Lakhs

Thank you!

Website www.prevestdenpro.com

